Ann: USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX, page-4

The timing of these two new patents, just prior to forthcoming data results, is perfect.
"The first allowance bears relevance to claims involving the intravenous dosing schedule of PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.

The second allowance has allowed claims bearing particular relevance to Prescient’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes." (4/8/16 Proactive Investors).
That is, with both the clinical trials to end before Xmas this year in their respective phase 1b, it's great to have approved patent privileges not only for commencement into phase 2 trails but most importantly a pre-requisite seen by most deals made.
Luck to us that hold.